BETHESDA, Md., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP ), a global biopharmaceutical company, today announced that it will host its fourth quarter and full year 2014 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, March 4, 2015. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.
Individuals interested in accessing the live audio webcast of the teleconference may do so at http://investor.sucampo.com/phoenix.zhtml?c=2...l-calendar and should log on 10 to 15 minutes before the teleconference begins to download any software required. Presentation slides will be available via the webcast link. A replay of the webcast will also be available on Sucampo's website for several days after the live event. Alternatively, individuals may dial 866-515-2907 (domestic) or 617-399-5121 (international) and use passcode 29558635. A replay of the teleconference will be available by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 17930617, approximately two hours after the teleconference concludes. The archive of the teleconference will be available for 30 days.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has one marketed product – AMITIZA ® – and a pipeline of drug candidates in clinical development. A global company, Sucampo is headquartered in Bethesda, Maryland, and has operations in Japan, Switzerland and the United Kingdom. For more information, please visit www.sucampo.com .
The Sucampo logo is the registered trademark and the tagline, The Science of Innovation, is a registered trademark of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; the ability of Sucampo to develop and commercialize existing and pipeline products; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally; the effects of competitive products on Sucampo's products; and the exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 10-K as filed with the Securities and Exchange Commission on March 12, 2014 as well as its filings with the Securities and Exchange Commission on Form 10-Q and 8-K, which Sucampo incorporates by reference.
Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications Sucampo Pharmaceuticals, Inc. 1-240-223-3718
